Literature DB >> 32931161

Impact of the COVID-19 pandemic on cytology practice: An international survey in the Asia-Pacific region.

Yeh-Han Wang1,2,3, Andrey Bychkov4,5, Indranil Chakrabarti6, Deepali Jain7, Zhiyan Liu8, Shurong He9, Sitti Fatimah Hanum10, Ikmal Bakrin11, Felipe Templo12, Truong Nguyen13, Priyanthi Kumarasinghe14,15, Chan Kwon Jung16, Kennichi Kakudo17, Chien-Chin Chen18,19.   

Abstract

BACKGROUND: The purpose of the current study was to examine the impact of coronavirus disease 2019 (COVID-19) on various aspects of cytology practice in the Asia-Pacific region.
METHODS: An online questionnaire was distributed to cytopathology laboratories in 24 Asia-Pacific countries to explore the impact of restrictive measures on access to health care, use of general and personal protective equipment (PPE), and changes in cytology workflow and workload from February to April 2020.
RESULTS: A total of 167 cytopathology laboratories from 24 countries responded to the survey; the majority reported that restrictive measures that limited the accessibility of health care services had been implemented in their cities and/or countries (80.8%) and their hospitals (83.8%). The respondents noted that COVID-19 had an impact on the cytologic workflow as well as the workload. Approximately one-half of the participants reported the implementation of new biosafety protocols (54.5%) as well as improvements in laboratory facilities (47.3%). Rearrangement or redeployment of the workforce was reported in 53.3% and 34.1% of laboratories, respectively. The majority of the respondents reported a significant reduction (>10%) in caseload associated with both gynecological (82.0%) and nongynecological specimens (78.4%). Most laboratories reported no significant change in the malignancy rates of both gynecological (67.7%) and nongynecological specimens (58.7%) compared with the same period in 2019.
CONCLUSIONS: The results of the survey demonstrated that the COVID-19 pandemic resulted in a significant reduction in the number of cytology specimens examined along with the need to implement new biosafety protocols. These findings underscore the need for the worldwide standardization of biosafety protocols and cytology practice.
© 2020 American Cancer Society.

Entities:  

Keywords:  biosafety; coronavirus; coronavirus disease 2019 (COVID-19); cytology; laboratories; pathology

Year:  2020        PMID: 32931161     DOI: 10.1002/cncy.22354

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  8 in total

1.  Effects of COVID-19 pandemic on cytology: specimen adequacy in fine-needle aspiration of palpable head and neck masses.

Authors:  Kimmie Rabe; Aastha Chauhan; Jana Holler; Tetyana Mettler; Khalid Amin; Jimmie Stewart
Journal:  J Am Soc Cytopathol       Date:  2022-04-19

2.  Cytopathology practice during the COVID-19 postlockdown: An Italian experience.

Authors:  Elena Vigliar; Rima Cepurnaite; Antonino Iaccarino; Pasquale Pisapia; Caterina De Luca; Umberto Malapelle; Claudio Bellevicine; Giancarlo Troncone
Journal:  Cancer Cytopathol       Date:  2021-02-17       Impact factor: 4.264

3.  Risk factors associated with physician trainee concern over missed educational opportunities during the COVID-19 pandemic.

Authors:  Sunny S Lou; Charles W Goss; Bradley A Evanoff; Jennifer G Duncan; Thomas Kannampallil
Journal:  BMC Med Educ       Date:  2021-04-17       Impact factor: 2.463

Review 4.  The Biosafety and Risk Management in Preparation and Processing of Cerebrospinal Fluid and Other Neurological Specimens With Potential Coronavirus Infection.

Authors:  Chien-Chin Chen; Pei-Chun Chiang; Tsung-Hsien Chen
Journal:  Front Neurol       Date:  2021-01-20       Impact factor: 4.003

5.  Financial and educational impact of the COVID-19 pandemic in an academic hospital-based tertiary cytopathology practice.

Authors:  Kanish Mirchia; Kamal Khurana
Journal:  J Am Soc Cytopathol       Date:  2021-09-02

6.  Brazil's health system functionality amidst of the COVID-19 pandemic: An analysis of resilience.

Authors:  Alessandro Bigoni; Ana Maria Malik; Renato Tasca; Mariana Baleeiro Martins Carrera; Laura Maria Cesar Schiesari; Dante Dianezi Gambardella; Adriano Massuda
Journal:  Lancet Reg Health Am       Date:  2022-03-05

7.  COVID-19 pandemic impact on cytopathology practice in the post-lockdown period: An international, multicenter study.

Authors:  Elena Vigliar; Pasquale Pisapia; Filippo Dello Iacovo; Eduardo Alcaraz-Mateos; Greta Alì; Syed Z Ali; Zubair W Baloch; Claudio Bellevicine; Massimo Bongiovanni; Pavlina Botsun; Dario Bruzzese; Lukas Bubendorf; Reinhard Büttner; Sule Canberk; Arrigo Capitanio; Chiara Casadio; Eugeniu Cazacu; Beatrix Cochand-Priollet; Alessandro D'Amuri; Katelynn Davis; Catarina Eloy; Marianne Engels; Guido Fadda; Gabriella Fontanini; Franco Fulciniti; Paul Hofman; Antonino Iaccarino; Antonio Ieni; Xiaoyin Sara Jiang; Kennichi Kakudo; Izidor Kern; Ivana Kholova; Kathryn M Linton McDermott; Chinhua Liu; Anandi Lobo; Maria D Lozano; Umberto Malapelle; Zahra Maleki; Pamela Michelow; Michael W Mikula; Jamal Musayev; Gonca Özgün; Meltem Oznur; Francisca Maria Peiró Marqués; David Poller; Michal Pyzlak; Betsy Robinson; Esther Diana Rossi; Sinchita Roy-Chowdhuri; Mauro Saieg; Spasenija Savic Prince; Fernando C Schmitt; Francisco Javier Seguí Iváñez; Tajana Štoos-Veić; Oksana Sulaieva; Brenda J Sweeney; Giovanni Tuccari; Marie-Louise van Velthuysen; Paul A VanderLaan; Philippe Vielh; Patrizia Viola; Quirinus J M Voorham; Birgit Weynand; Pio Zeppa; William C Faquin; Martha Bishop Pitman; Giancarlo Troncone
Journal:  Cancer Cytopathol       Date:  2022-01-10       Impact factor: 4.264

8.  SARS-CoV-2 RNA may rarely be present in a uterine cervix LBC sample at the asymptomatic early stage of COVID 19 disease.

Authors:  Ondrej Ondič; Kateřina Černá; Iva Kinkorová-Luňáčková; Jana Němcová; Bořivoj Mejchar; Jan Chytra; Jiří Bouda
Journal:  Cytopathology       Date:  2021-05-31       Impact factor: 1.286

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.